SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · Adults with COPD
1 finding from 1 review
FEV1 · Adults with COPD
1 finding from 1 review
Difference vs placebo in adjusted peak FEV1 (3‐week to 6‐month · Adults with COPD
1 finding from 1 review
Adverse events (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in adverse events (3‐week to 1‐year compared with placebo (high certainty).
1 finding from 1 review
Quantity of drinking (g/week) at 12 months · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Quantity of drinking (g/week) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Frequency of binge drinking (no. binges/wk) at 12 months ‐ not measured · people with hazardous or harmful alcohol consumption
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of drinking (no. days drinking/week) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Drinking Intensity · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Frequency of drinking (no. binges/wk) at 12 months · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Frequency of drinking (no. days drinking/week) at 12 months · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Drinking Intensity · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Adverse effects · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Quantity of drinking (g/week) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Frequency of drinking (no. binges/wk) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Frequency of drinking (no. days drinking/week) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Drinking Intensity · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Treatment failure Need for additional treatment · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in treatment failure Need for additional treatment compared with SCS treatment (moderate certainty).
1 finding from 1 review
Relapse New acute exacerbation or COPD‐related admission · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in relapse New acute exacerbation or COPD‐related admission compared with SCS treatment (moderate certainty).
1 finding from 1 review
Adverse drug effect—hyperglycaemia · exacerbations of COPD
SCS treatment for 7 or fewer days showed no clear difference in adverse drug effect—hyperglycaemia compared with SCS treatment (moderate certainty).
1 finding from 1 review